Rawcliffe Adrian 4
4 · Adaptimmune Therapeutics PLC · Filed Jan 17, 2024
Insider Transaction Report
Form 4
Rawcliffe Adrian
DirectorChief Executive Officer
Transactions
- Award
Option to purchase Ordinary Shares
2024-01-15+7,633,296→ 7,633,296 totalExercise: $0.14Exp: 2034-01-15→ Ordinary Shares (7,633,296 underlying) - Award
Option to purchase Ordinary Shares
2024-01-15+1,696,272→ 1,696,272 totalExercise: $0.00→ Ordinary Shares (1,696,272 underlying)
Footnotes (5)
- [F1]The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 1,908,324 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 159,024 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 159,132 Ordinary Shares on January 15, 2028.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 424,068 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 424,068 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.
- [F5]The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.